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ABSTRACT: Introduction: Hereditary transthyretin (hATTR)
amyloidosis is a progressive, degenerative disease, with peripheral
neuropathy, cardiomyopathy, and other clinical manifestations. In
this study we examine the impact of hATTR amyloidosis on quality
of life (QOL). Methods: Neuropathy-specific QOL, measured with
the Norfolk QOL-Diabetic Neuropathy questionnaire, was compared
between patients with hATTR amyloidosis and patients with type 2
diabetes, whereas generic QOL, measured with the 36-item Short
Form Health Survey version 2 (SF-36v2), was compared between
patients with hATTR amyloidosis, the general population, and
patients with chronic diseases. Results: Neuropathy-specific QOL
for patients with hATTR amyloidosis was nearly equivalent to that of
patients with type 2 diabetes with diabetic neuropathy accompanied
by a history of ulceration, gangrene, or amputation. Generic QOL
was worse than that seen in the general population, with physical
functioning worse than that for patients with multiple sclerosis and
congestive heart failure. Discussion: Patients with hATTR amyloid-
osis show significant burden on QOL, particularly in physical
functioning.
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Systemic amyloidoses are a set of diseases defined
by the extracellular presence of misfolded protein
deposits, known as amyloids, in organs and tissue.1,2
With sufficient buildup, these deposits interfere with
normal tissue structure and function, eventually lead-
ing to organ failure and death.3 Amyloid transthyretin
(ATTR) amyloidosis, the most common subtype of
amyloidosis, involves amyloid deposits of misfolded
transthyretin (TTR) protein that is produced primarily
in the liver.4,5
A genetic mutation for developing ATTR amyloid-
osis can be inherited, although a nongenetic variation
of the disease (wild-type) has been identified.6,7
Hereditary ATTR (hATTR) amyloidosis is a progres-
sive, degenerative, and fatal disease.6,8 Recent esti-
mates place its worldwide prevalence at 50,000
people,8 although it is thought to be significantly
underdiagnosed.
hATTR amyloidosis is a systemic disease and typically
involves amyloid deposits in multiple organ systems,
commonly in peripheral nerves and cardiomyocytes.4,9
Deposit buildup in peripheral nerves leads to symptoms
of peripheral neuropathy, in which patients initially
experience sensory difficulties such as paresthesia, hypo-
esthesia, and pain in the hands and feet, that progresses
proximally and eventually includes motor involvement,
resulting in loss of ambulation. This pattern of progres-
sion is similar to that observed in diabetic neuropathy,
although the rate of progression is much more rapid in
hATTR amyloidosis. Deposits of TTR amyloid in the
myocardium lead to a restrictive cardiomyopathy, which
is characterized by shortness of breath, arrhythmia, and
eventual cardiac failure. Patients with hATTR amyloid-
osis also commonly experience autonomic neuropathy,
gastrointestinal, ocular, and renal dysfunction, and car-
pal tunnel syndrome.8
Empirical findings indicate that patients with hATTR
amyloidosis carry a significant disease burden that
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impacts quality of life (QOL). A recent study examining
12-item Short Form Health Survey version 2 (SF-12v2)
scores of patients with ATTR amyloidosis showed sub-
stantial burden on physical health, with scores on the
Physical Component Summary (PCS) 1.7 standard devi-
ations below those of the general United States popula-
tion.10 Another study, examining patients with ATTR
amyloidosis with polyneuropathy on the EuroQol 5-
Dimension (EQ-5D) questionnaire, showed that the
mean health utility score for patients was 0.50, far below
the mean score for the general population (0.76).11 A
clear relationship between increasing duration of symp-
toms of patients with ATTR amyloidosis with symptom-
atic polyneuropathy and worsening scores on the
Norfolk Quality of Life–Diabetic Neuropathy (Norfolk
QOL-DN) questionnaire has been established.12,13 The
information lacking in the current literature, however, is
a contextualization of the burden in hATTR amyloid-
osis, such as how it compares with the burden of other,
more well-understood medical conditions. Also
unknown is the impact of hATTR amyloidosis on spe-
cific domains of QOL, as previous studies have only
examined its impact via summary or total scores of QOL
measures.
In our study we aimed to further explore the bur-
den of hATTR amyloidosis with polyneuropathy on
QOL in a clinical trial sample and provide an inter-
pretive context through which we may better under-
stand the QOL burden in this patient population.
METHODS
Data Sources. Norfolk QOL-DN scores were compared
among patients with hATTR amyloidosis with polyneuropathy
from a clinical trial and a sample of patients with type 2 diabe-
tes from a cross-sectional study. SF-36v2 scores were compared
among patients with hATTR amyloidosis with polyneuropathy
in a clinical trial, a general population sample, and patients
with 1 of 5 chronic conditions.
NEURO-TTR Sample. Patients with hATTR amyloid-
osis with polyneuropathy enrolled in the NEURO-TTR trial
(Clinical Trials ID # NCT01737398; ClinicalTrials.gov) were
included in all analyses. NEURO-TTR was a phase III, multina-
tional, randomized, double-blind, placebo-controlled study of
the efficacy of inotersen in patients with hATTR amyloidosis
with polyneuropathy. The primary objective of NEURO-TTR
was to evaluate the efficacy of inotersen in slowing or halting
nerve damage caused by TTR amyloid deposits.
Patients with hATTR amyloidosis were randomized in a 2:1
ratio to receive either a single subcutaneous injection of 1.5 ml
of inotersen or placebo, respectively, 3 times in the first week
and then once weekly for a 65-week treatment period. Patients
were eligible to participate in the study if they had stage 1 (ambu-
latory without assistance) or stage 2 (ambulatory with assistance
such as a cane or walker) disease severity,14 and a neuropathy
impairment score (NIS) between 10 and 130 (inclusive).
Patients were stratified into treatment arms based on 3 subgroup
factors: previous treatment with tafamidis or diflunisal vs. neither;
stage 1 vs. stage 2 ambulatory disability; and Val30Met TTR muta-
tion vs. non-Val30Met TTR mutation.
The trial protocol was approved by institutional review
boards or local ethics committees. All patients provided writ-
ten informed consent to participate in the trial.
Type 2 Diabetes Sample. Also included in the analysis
comparing Norfolk QOL-DN scores is a sample of patients
with type 2 diabetes described by Veresiu et al.15 This sample
consisted of 20,469 patients from Romania (mean age 60.9
years; 53% female) who consented to participate in a cross-sec-
tional study for which they provided scores on the Norfolk QOL-
DN as well as self-reported disease status. Based on the latter,
patients were classified as follows: diabetes without DN
(n = 6,615); diabetes with DN and no history of ulceration, gan-
grene, or amputations (n = 10,704); or diabetes with DN and a
history of ulceration, gangrene, or amputations (n = 3,150).
General Population and Condition Benchmark
Samples. Benchmark samples used for comparison of SF-36v2
scores with the NEURO-TTR sample were drawn from 2 sepa-
rate sources. First, SF-36v2 data were drawn from a normative
general population sample collected as part of the QualityMetric
2009 Norming Study (QMNS), a probabilistic online survey of
4,040 noninstitutionalized adults in the United States.16 Along
with measures of QOL, the QMNS survey included a checklist of
30 chronic conditions. In addition to the full QMNS general
population sample, respondents who indicated having congestive
heart failure (CHF; n = 137) or irritable bowel syndrome (IBS;
n = 321) were selected for use as condition-specific benchmarks
for comparison with the NEURO-TTR sample, due to their hav-
ing overlapping symptoms with hATTR amyloidosis.
Second, SF-36v2 scores from condition-specific benchmark
samples were drawn from Kantar Health’s National Health
and Wellness Survey (NHWS), an annual international online
panel survey of health care in a representative sample of
adults. The NHWS includes a variety of patient-reported out-
come (PRO) measures of health status and QOL, including
the SF-36v2. Respondents are asked to indicate having experi-
enced any of dozens of different health conditions. Compari-
sons were made between scores of the NEURO-TTR sample
and those from NHWS respondents who indicated having
experienced 1 of the following chronic health conditions,
each of which shares some symptoms with hATTR amyloidosis:
Crohn’s disease (CD; n = 2,059); DN (n = 5,682); or multiple
sclerosis (MS; n = 1,901). SF-36v2 data from respondents in
the USA who participated in the 2015 or 2016 (pooled)
NHWS were included in the current analysis.
Both the QMNS and NHWS studies utilized enrolled
panels, with respondents providing written consent and agree-
ing to the use of their responses in group-level analyses. Data
collection for both was performed by survey companies
through their existing approved panels, following their own
procedures. Consequently, no specific ethics committee or
institutional review board approval was required.
Assessment Instruments. Neuropathy-related QOL was
assessed using the Norfolk QOL-DN, a PRO measure assessing
the impact of several aspects of DN on patients’ QOL.17 The
Norfolk QOL-DN yields a total score based on all 35 items
(score range from −4 to 136), and scores on 5 subscales cap-
turing symptoms associated with damage to nerve fibers: physi-
cal functioning/large-fiber neuropathy (15 items; score range
−4 to 56); activities of daily living (ADL; 5 items; score range
0–20); symptoms (8 items; score range 0–32); small-fiber neu-
ropathy (4 items; score range 0–16); and autonomic
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neuropathy (3 items; score range 0–12). In all cases, higher
scores indicate worse functioning.
Generic QOL was assessed using the SF-36v2 (with 4-week
recall), a 36-item PRO measure of functional health and well-
being.16 Responses to items are used to compute scores for 8
domains of QOL: physical functioning; role limitations due to
physical health (role-physical); bodily pain; general health;
vitality; social functioning; role limitations due to emotional
health (role-emotional); and mental health. Two summary
scores, the PCS and Mental Component Summary (MCS),
capturing global physical health and global mental health,
respectively, can be calculated using weighted scores from the
8 domains.
All SF-36v2 domains and summary scores can be calculated
as T-scores using norm-based methods, standardized to a
mean of 50 and a standard deviation of 10 in the general pop-
ulation. Higher SF-36v2 scores reflect better QOL.
Group-level minimally important difference (MID) values
have been established for the SF-36v2 using both distribution-
based and anchor-based methods.16 Defined as the smallest dif-
ferences in scores that patients would consider as beneficial
and for which a clinician would recommend adjusting patients’
care, MID threshold values can facilitate interpretation of
whether group-level differences are clinically meaningful.18 The
established MID threshold value is 3 points for physical func-
tioning, role-physical, bodily pain, social functioning, and men-
tal health domains, as well as for MCS. The MID threshold
value is 2 points for general health and vitality domains, as well
as for PCS, and 4 points for the role-emotional domain.
Analysis of Burden of hATTR Amyloidosis on Neuropathy-
Related QOL. To estimate the burden of hATTR amyloid-
osis on patients’ neuropathy-related QOL, descriptive analyses
were conducted in which baseline Norfolk QOL-DN scores
from the NEURO-TTR sample were compared with scores for
type 2 diabetes patients in the study by Veresui et al.15
Analysis of Burden of hATTR Amyloidosis on Generic
QOL. To estimate the burden of hATTR amyloidosis on
patients’ QOL, post-hoc analyses were conducted in which base-
line SF-36v2 scores from NEURO-TTR patients were com-
pared with scores from the general population and chronic
condition–specific benchmark samples. For each comparison,
data from the benchmark samples were adjusted to match the
age and gender distribution of the NEURO-TTR sample using
ordinary least-squares regression methods. Univariate analysis
of variance (ANOVA) models were used to test for statistically
significant differences in each of the domain and summary
mean scores between the NEURO-TTR sample and adjusted
mean scores for each of the benchmark samples. The magnitude
of burden was interpreted using 3 different criteria: statistical
significance of mean differences (α = 0.05); group-level MID
threshold values to indicate clinical significance; and Cohen’s d
standardized mean differences to estimate magnitude of effect
size, the latter of which were interpreted according to Cohen’s
published guidelines (d = 0.2, small effect; d = 0.5, medium
effect; d = 0.8, large effect).19
To provide further interpretive context on the burden of
physical functioning, item-level comparisons between the
NEURO-TTR sample and benchmark samples were conducted
for each of the 10 physical functioning items on the SF-36v2.
These physical functioning items, each referring to one of a
variety of common physical activities, have 3 response options:
“Limited a lot”; “Limited a little”; or “Not limited at all.” In this
analysis, the percentage of patients who chose the “Limited a
lot” option was tallied and descriptively compared between the
NEURO-TTR sample and each of the benchmark samples.
In addition to comparisons across benchmark samples, the
magnitude of burden relative to the general population was
examined between subgroups of patients in the NEURO-TTR
sample defined by clinically important characteristics. Sepa-
rate comparisons between the NEURO-TTR sample and age-
and gender-adjusted general population scores were made
between patients with early (≤50 years) vs. late (>50 years) age
of symptom onset; patients with stage 1 vs. stage 2 ambulatory
disability; and patients with cardiomyopathy vs. those without
cardiomyopathy.
RESULTS
Sample Characteristics. Baseline Norfolk QOL-DN
and SF-36v2 data were collected from a total of 172
patients with hATTR amyloidosis enrolled in the
safety set of the NEURO-TTR study. Sample demo-
graphics and selected disease characteristics of this
sample are presented in Table S1 in the Supplemen-
tary Material (available online).
Analysis of Burden of hATTR Amyloidosis on Neuropathy-
Related QOL. Norfolk QOL-DN mean total score
(Table 1) was 48.4 points for the NEURO-TTR sample,
which was much higher (worse) than scores from type
2 diabetes patients in the study by Veresui et al.15 who
had no DN or DN and no history of ulceration, gan-
grene, or amputation, but quite similar to those who
had DN accompanied by ulceration, gangrene, or
amputation. Similar patterns were observed for most
Norfolk QOL-DN subscales: mean scores for the
NEURO-TTR sample were most similar to those for
patients with DN and ulceration, gangrene, and ampu-
tation for physical functioning/large-fiber neuropathy,
Table 1. Mean (standard error) scores of the Norfolk QOL-DN questionnaire subscales for hATTR and type 2 diabetes patient samples.
Subscale
NEURO-TTR trial
(n = 172)
Veresiu et al.15
Diabetes without
DN (n = 6,615)
Diabetes with DN, without ulceration,
gangrene, amputation (n = 10,704)
Diabetes with DN, with ulceration, gangrene,
amputation (n = 3,150)
Total 48.4 (2.08) 13.7 (0.23) 34.9 (0.24) 50.4 (0.49)
PF/large fiber 24.3 (1.12) 7.9 (0.13) 18.8 (0.13) 25.6 (0.26)
ADL 6.3 (0.44) 1.19 (0.04) 3.5 (0.04) 5.9 (0.10)
Symptoms 10.6 (0.47) 2.8 (0.05) 8.0 (0.05) 11.2 (0.11)
Small fiber 5.1 (0.33) 0.8 (0.03) 2.8 (0.03) 4.9 (0.08)
Autonomic 2.1 (0.21) 1.0 (0.02) 2.0 (0.02) 3.2 (0.05)
ADL, activities of daily living; DN, diabetic neuropathy; PF, physical functioning.
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ADLs, symptoms, and small-fiber neuropathy. Scores
on the autonomic subscale were closest to those for
patients with DN and no history of ulceration, gan-
grene, or amputation.
Analysis of Burden of hATTR Amyloidosis on Generic
QOL. Burden of hATTR Amyloidosis Relative to General
Population Norms. When compared with age- and
gender-adjusted general population norms, mean
baseline scores from the NEURO-TTR sample
showed considerable QOL burden in all physical
domains and for PCS (P < 0.001 for all; Fig. 1). The
NEURO-TTR sample exhibited the greatest deficits
in physical functioning and role-physical domains
(Cohen’s d ≥ 0.74 for both), with deficits greater than
10 points when compared with the general population.
Considerable burden was also observed for the percep-
tion of general health domain, which had a deficit of 8
points (d = 0.53). Mean differences between the
NEURO-TTR sample and the general population
exceeded the MID thresholds for all mental-based
domains except for mental health and MCS.
Burden of hATTR Amyloidosis Relative to Condition-
Specific Benchmarks. Comparisons between the
NEURO-TTR samples’ baseline SF-36v2 scores and
several of the condition-specific benchmarks showed rel-
ative burden of hATTR amyloidosis on patients’ physical
functioning (Fig. 2). Patients with hATTR amyloidosis
showed clinically meaningful deficits (i.e., exceed
group-level MID threshold values) on physical function-
ing relative to CD (d = 0.28), DN (d = 0.27), and IBS
(d = 0.73) benchmarks (P < 0.001 for all), although not
with CHF or MS (both d < 0.10). Correspondingly, dif-
ferences between hATTR amyloidosis patients’ PCS
scores and those from these 3 benchmark comparators
as well as MS also exceeded MID thresholds (>2 points
for all differences). The NEURO-TTR sample reported
less burden on global mental well-being relative to each
of the condition-specific benchmarks (Fig. 3; P < 0.005;
FIGURE 1. Mean SF-36v2 scores for the hATTR patient sample
relative to age- and gender-matched general population norms.
hATTR, hereditary ATTR amyloidosis; MCS, Mental Component
Summary; PCS, Physical Component Summary. Error bars repre-
sent standard errors of means. P < 0.05 for all comparisons. All dif-
ferences exceeded minimally important difference (MID) thresholds
except for mental health and MCS. Magnitude of effect sizes
(Cohen’s d-values) for differences were as follows: physical function-
ing (d = 0.90); role-physical (0.74); bodily pain (0.37); general health
(0.53); vitality (0.33); social functioning (0.43); role-emotional (0.35);
mental health (0.17); PCS (0.82); and MCS (0.11).
FIGURE 2. Mean SF-36v2 physical health scores for the hATTR
patient sample relative to age- and gender-matched chronic condition
benchmarks. CD, Crohn’s disease; CHF, congestive heart failure;
DN, diabetic neuropathy; hATTR, hereditary ATTR amyloidosis; IBS,
irritable bowel syndrome; MS, multiple sclerosis; PCS, Physical Com-
ponent Summary. Error bars represent standard errors of means.
FIGURE 3. Mean SF-36v2 psychological and social health scores
for the hATTR patient sample relative to age- and gender-matched
chronic condition benchmarks. CD, Crohn’s disease; CHF, conges-
tive heart failure; DN, diabetic neuropathy; hATTR, hereditary
ATTR amyloidosis; IBS, irritable bowel syndrome; MCS, Mental
Component Summary; MS, multiple sclerosis. Error bars represent
standard errors of mean.
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Cohen’s d = 0.33–0.64 for MCS) with the exception of
IBS (P = 0.33; Cohen’s d = 0.08 for MCS).
Burden of hATTR Amyloidosis on Physical Functioning
Relative to General Population and Chronic Condition
Benchmarks. The percentage of patients indicating
they were “Limited a lot” for each SF-36v2 physical
functioning item from the NEURO-TTR sample and all
benchmark samples are reported in Table 2. The per-
centage of patients in the NEURO-TTR sample
selecting the “Limited a lot” option was substantially
greater than that of the general population for all physi-
cal functioning items, with the exception of “bathing/
dressing.” Patients in the NEURO-TTR sample were
more likely to endorse “Limited a lot” when compared
with patients in the other chronic condition samples on
6 of 10 items, including the ability to engage in vigorous
activities (such as running, lifting heavy objects, or par-
ticipating in strenuous sports), ability to engage in mod-
erate activities (such as moving a table, pushing a
vacuum cleaner, bowling, or playing golf), lifting/carry-
ing groceries, climbing several flights of stairs, bending/
kneeling/stooping, and walking more than 1 mile.
Burden of hATTR Amyloidosis on Patient Subgroups
Relative to the General Population. The magnitude of
burden relative to general population norms was
assessed between key subgroups of patients in the
NEURO-TTR sample (see Figs. S1–3 online). Relative
to the general population, patients in the NEURO-TTR
sample with early onset of symptoms (beginning at or
before 50 years old) reported slightly larger deficits in
QOL than patients whose symptoms first occurred
later in life, with the largest differences in bodily pain
and perception of general health (see Fig. S1 online).
Relative to the general population, patients in the
NEURO-TTR sample with stage 2 ambulatory disabil-
ity reported markedly more QOL burden than
patients with stage 1 ambulatory disability (see Fig. S2
online), with differences on the majority of domains.
When compared with the general population, patients
in the NEURO-TTR sample with cardiomyopathy
reported substantially more physical QOL burden than
patients without cardiomyopathy (see Fig. S3 online),
particularly for physical functioning, role-physical,
general health, and vitality domains.
DISCUSSION
Previous studies10,11 have documented that patients
with hATTR amyloidosis experience a burden on
QOL, particularly with regard to physically oriented
QOL (e.g., the PCS on the SF-12v2), whereas other
studies have shown a burden on neuropathy-related
QOL, which increases with symptom duration.12 The
purpose of the current analysis was to provide a con-
text for interpreting the magnitude of burden of
hATTR amyloidosis on both generic and neuropathy-
related QOL.
The analysis of neuropathy-related QOL found
that the burden experienced by patients with hATTR
amyloidosis is nearly equivalent to that of patients
with type 2 diabetes who have DN accompanied by a
history of ulceration, gangrene, or amputation. Our
analysis also showed a substantial burden on physical
aspects of QOL for patients with hATTR amyloidosis
relative to the general population, particularly for
physical functioning, role-physical, and perception of
general health. The burden on physical functioning
for patients with hATTR amyloidosis was worse than
that of patients with CD, DN, IBS, and is comparable
to that of patients with MS and CHF.
The largest deficit for patients with hATTR amy-
loidosis with symptoms of polyneuropathy was
observed in physical functioning. This is consistent
with the types of clinical manifestations experienced
by these patients, which includes a length-dependent
sensory and motor neuropathy that starts in the
hands and feet and moves proximally, eventually
leading to a wheelchair or bedbound state. The
cohort of patients with hATTR amyloidosis enrolled
Table 2. Percentage of patients selecting the “Limited a lot” option for SF-36v2 physical functioning items.
General population
(n = 4,040)
hATTR
(n = 172)
CHF
(n = 141)
IBS
(n = 321)
CD
(n = 2,059)
DN
(n = 5,682)
MS
(n = 1,901)
Age [mean (SD)] 50.9 (17.3) 59.2 (13.0) 61.7 (15.7) 53.5 (16.7) 42.7 (15.0) 57.7 (13.9) 45.1 (14.7)
Male [n (%)] 1,995 (49.4) 118 (68.6) 79 (56.0) 109 (34.0) 1178 (57.2) 3,288 (57.9) 893 (47.0)
Item Content
PF01 Engage in vigorous activities 26% 80% 67% 42% 51% 68% 61%
PF02 Engage in moderate activities 9% 43% 27% 18% 25% 28% 32%
PF03 Lifting/carrying groceries 6% 34% 19% 12% 22% 21% 27%
PF04 Climbing several flights of stairs 14% 58% 47% 24% 27% 44% 41%
PF05 Climbing one flight of stairs 6% 26% 23% 11% 23% 25% 30%
PF06 Bending/kneeling/stooping 11% 39% 30% 18% 24% 33% 29%
PF07 Walking >1 mile 17% 57% 50% 27% 31% 50% 44%
PF08 Walking several hundred yards 9% 36% 36% 15% 26% 33% 34%
PF09 Walking 100 yards 6% 16% 23% 9% 23% 24% 30%
PF10 Bathing/dressing 2% 7% 7% 2% 18% 9% 18%
CD, Crohn’s disease; CHF, congestive heart failure; DN, diabetic neuropathy; hATTR, hereditary ATTR amyloidosis; IBS, irritable bowel syndrome; MS, multi-
ple sclerosis; PF, physical functioning.
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in the NEURO-TTR trial and analyzed here included
early- to mid-stage patients (67% stage 1, 33% stage
2); stage 3 patients (wheelchair or bed-bound)
were excluded from enrolling in the NEURO-TTR
trial.
Examination of responses from patients with
hATTR amyloidosis to individual items from the
physical functioning domain of the SF-36v2 provides
a more concrete interpretation of difficulties faced
by patients with early- to mid-stage hATTR amyloid-
osis. The proportion of patients reporting severe
impairment in physical activities ranged from 7%
who were limited a lot in bathing and dressing them-
selves to 80% who were limited a lot in vigorous activi-
ties (e.g., running, lifting heavy objects, participating in
strenuous sports). Results from the item-level analyses
indicate that more patients with hATTR amyloidosis
than patients with CHF, IBS, CD, DN, or MS had
severe difficulty in engaging in vigorous activities, mod-
erate activities, lifting/carrying groceries, climbing sev-
eral flights of stairs, bending/kneeling/stooping, and
walking more than 1 mile. For other aspects of physical
functioning, such as climbing one flight of stairs or
walking several hundred yards, patients with hATTR
amyloidosis showed similar burdens as those with CHF,
DN, and MS.
A previous study using the SF-12v2, which is a sub-
set of 12 items from the SF-36v2 and is scored similarly,
showed substantial burden for patients with ATTR
amyloidosis on physical-oriented QOL (PCS = 33.6)
but not on mental-oriented QOL (MCS = 47.1).10 Our
findings with respect to summary component measures
are quite consistent: the NEURO-TTR sample showed
considerable burden on physically oriented QOL
(PCS = 36.2), with seemingly no burden on mental-ori-
ented QOL (MCS = 50.5). However, by examining the
domains of the SF-36v2, we get a more precise under-
standing of the actual mental burden experienced by
this patient population. In particular, in the NEURO-
TTR sample we can see that there is clinically meaning-
ful burden on several scales that contribute positively
to the scoring of MCS, including vitality (mean = 45.9),
social functioning (mean = 43.7), and role-emotional
(mean = 45.2) scales, which would not be evident from
examining the MCS on its own. This distinction points
to the importance of going beyond total and summary
scores of QOL measures and looking at scores on par-
ticular domains to get a richer profile of patients’ expe-
riences with the disease.
As expected, physical burden for patients with
hATTR amyloidosis varied as a function of key clini-
cal indicators. The burden on bodily pain and per-
ception of general health was greater for patients
with early onset of symptoms than those with late
onset. Patients with stage 2 ambulatory disability and
those with cardiomyopathy showed considerably
more burden on physical functioning, role-physical,
and perception of general health domains, as well as
on global physical well-being, than did patients in
stage 1 and without cardiomyopathy, respectively.
These findings show that progression of the disease,
such as greater buildup of TTR amyloids in the
peripheral nervous system and cardiac tissue, is asso-
ciated with an increasing burden on the QOL of
patients with hATTR amyloidosis.
The rarity of hATTR amyloidosis and the variabil-
ity of its clinical manifestations make early diagnosis
difficult.8,20 Further, available treatments for this dis-
ease (liver transplantation or pharmacotherapy) may
limit production of new amyloid fibrils, but may not
able to remove existing fibril deposits from the tis-
sue, meaning the pathology and clinical symptoms
are typically nonreversible. Thus, to minimize bur-
den of disease, early diagnosis and treatment of the
disease is essential, so that treatment can preserve
QOL in patients while QOL is still viable.
There are several limitations of our study. One
limitation is that the clinical trial with patients with
hATTR amyloidosis excluded those who were already
nonambulatory or had advanced neurological dis-
ability. Thus, the degree of burden is likely under-
estimated in the current sample. Caution should
therefore be used when generalizing these findings
to other hATTR samples, particularly to those with
a higher percentage of patients in advanced stages
of the disease.
A second limitation to generalizability is the het-
erogeneity of TTR genotypes in the hATTR sample.
Approximately half of the patients had the Val30Met
mutation. The remaining subjects had 1 of 26 differ-
ent TTR mutations, with frequencies ranging from 1
(0.6%) to 22 (12.8%) of the subjects. The analyses
did not examine the impact of genotype on disease
burden, and therefore these findings may not gener-
alize to samples of patients with different mutations.
Another limitation rests on the different geographical
and cultural backgrounds of the populations for which
we are making comparisons. It is possible that, due to
cultural differences, responses on the Norfolk QOL-DN
may differ between the DN participants in the Eastern
European country of Romania (as in the study by
Veresiu et al.15) and patients enrolled in the NEURO-
TTR study who lived in 10 countries (Argentina, Brazil,
France, Germany, Italy, New Zealand, Portugal, Spain,
UK, and the USA) with potentially very different cul-
tures. Further, all benchmark samples for the compari-
sons of SF-36v2 scores included only subjects from the
USA. The impact of heterogeneity of cultural back-
grounds for each of the samples being compared on
our findings cannot be assessed.
Another limitation is that there is amismatch between
hATTR, a progressive and seemingly irreversible disor-
der, and treatable conditions for which QOL burden
can be alleviated after therapeutic interventions. Thus,
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interpreting findings when comparing burden across
these different disease types is not straightforward, and
these results should be interpreted with caution.
In conclusion, our analysis has shown a substantial
burden on neuropathy-related QOL and on physical
aspects of generic QOL for patients with hATTR amy-
loidosis, particularly with regard to physical functioning,
role limitations due to physical health problems, and
perception of general health. The finding that physical
burden was especially profound in patients with a
greater progression of disease points to the importance
of early diagnosis and treatment of this disease.
Portions of this study were presented at the Academy
of Managed Care Pharmacy Annual Meeting, April
2018, Boston, Massachusetts, and at the annual meeting
of the International Society for Pharmacoeconomics
and Outcomes Research, May 2018, Baltimore,
Maryland.
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